Jeremy Caldwell Ph.D Overview
- Company
- Inception Scienc...
- Primary Position
-
Chief Executive...
- Primary Industry
-
Healthcare
- Active Board Seats
-
2
- Med. Deal Size
-
- Med. Valuation
-
Jeremy Caldwell Ph.D General Information
Biography
Dr. Jeremy Caldwell served as Chief Executive Officer and President at Inception Sciences. He serves as a Board Member at BioGraph 55 and Sardona Therapeutics. He also served as a Venture Partner at Versant Ventures. He served as a Board Member at Belharra Therapeutics and Odyssey Thera. He served as Co-Chief Executive Officer and Board Member at Lycia Therapeutics. He served as a Board Member at Chinook Therapeutics. He serves as a Partner at Red Tree Venture Capital. A widely respected executive and scientist with deep industry expertise built through a decorated career in industry and venture activities, his accomplishments span from creating innovative drug development companies to driving the discovery, development, and translation of novel therapies. He has forged deep ties to the San Diego and San Francisco Bay Area biotechnology communities, as well as far-reaching relationships within the global pharmaceutical space. Most recently he was CEO of Inception Therapeutics, Versant Ventures' San Diego-based discovery engine for new company formation, a venture partner with Versant Ventures, and a member of the firm's investment team. In these roles, he co-led the formation of Chinook Therapeutics (acquired by Novartis for $3.5B), and co-led the investment and formation of Lycia Therapeutics, Belharra Therapeutics, Light Horse Therapeutics, among others, acting as founding CEO and board director of each. Before Inception/Versant, he was an entrepreneur-in-residence at Third Rock Ventures, where he participated in the genesis and formation of Revolution Medicines (RVMD), Pliant Therapeutics (PLRX), Decibel Therapeutics (DBTX), Relay Therapeutics (RLAY) and Nurix Therapeutics (NRIX). He also played key roles in the foundational science on which Rigel, Inc. (RIGL), and Kalypsys, Inc., were formed, as well as advising in the evolution of Syrrx, Inc. (acquired by Takeda for $270M). With drug discovery and development expertise primarily focused on oncology, immunology, neurology, and cardiometabolic disease, he is credited with significant contributions to research leading to four commercial drugs. He previously served as executive vice president and chief scientific officer at Ardelyx, Inc., where he advanced a portfolio of novel anti-fibrotic and cardiorenal therapeutics to the clinic. His career has also included key leadership roles with Sirna, Merck Research Laboratories, and the Genomics Institute of the Novartis Research Foundation (GNF). He is a member of the board of Sardona Therapeutics. He received a B.S. in molecular and cellular biology with an emphasis in neuroscience from the University of California at Berkeley and a Ph.D. in molecular pharmacology from Stanford University.
Contact Information
Address
- 4550 Norris Canyon Road
- Suite 140
- San Ramon, CA 94583
- United States
Jeremy Caldwell Ph.D Positions (1)
Firm name | Firm type | Title | Location | Industry | Since |
---|---|---|---|---|---|
Red Tree Venture Capital | Investor | Partner | Redwood City, CA | Venture Capital |
Jeremy Caldwell Ph.D Board Seats (3)
Company | Industry | Ownership Status | Financing Status | Location | Since |
---|---|---|---|---|---|
BioGraph 55 | Biotechnology | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA | |
Odyssey Thera | Drug Discovery | Out of Business | Formerly VC-backed | San Ramon, CA | |
Sardona Therapeutics | Discovery Tools (Healthcare) | Privately Held (backing) | Venture Capital-Backed | San Francisco, CA |
Jeremy Caldwell Ph.D Lead Partner on Deals (3)
Jeremy Caldwell Ph.D has been the lead partner on 3 deals. Their latest deal was with BioGraph 55, a biotechnology company. The deal was made for on 01-Jun-2024.
Company | Deal Date | Deal Type | Deal Size | Deal Status | Industry | Location |
---|---|---|---|---|---|---|
BioGraph 55 | 01-Jun-2024 | Later Stage VC (Series A1) | Completed | Biotechnology | San Francisco, CA | |
Lycia Therapeutics | 09-Sep-2021 | Completed | Drug Discovery | South San Francisco, CA | ||
Chinook Therapeutics | 22-Aug-2019 | Completed | Drug Discovery | Seattle, WA |
Jeremy Caldwell Ph.D Network (73)
Board Members (35)
Name | Company | Representing | Location | From |
---|---|---|---|---|
William Greenman | Chinook Therapeutics | Self | Seattle, WA | |
Robert Azelby | Chinook Therapeutics | Self | Seattle, WA | |
Belharra Therapeutics | Belharra Therapeutics | San Diego, CA | ||
Lycia Therapeutics | Cowen Healthcare Investments | South San Francisco, CA | ||
Chinook Therapeutics | Self | Seattle, WA |
Portfolio Executives (18)
Name | Company | Role | Deal date | Location |
---|---|---|---|---|
Paul Tumeh MD | BioGraph 55 | Founder, Chief Executive Officer & Board Member | 01-Jun-2024 | San Francisco, CA |
Alexander Johnson | BioGraph 55 | Chief Operating Officer | 01-Jun-2024 | San Francisco, CA |
BioGraph 55 | Executive | 01-Jun-2024 | San Francisco, CA | |
Lycia Therapeutics | Vice President of Finance | 09-Sep-2021 | South San Francisco, CA | |
Lycia Therapeutics | Chief Business Officer | 09-Sep-2021 | South San Francisco, CA |
Fund Team Members (20)
Name | Investor | Fund | Fund Location |
---|---|---|---|
Samad Wahid MD | Red Tree Venture Capital | Red Tree Venture Fund II | Redwood City, CA |
Samad Wahid MD | Red Tree Venture Capital | Red Tree Venture Fund | Redwood City, CA |
Red Tree Venture Capital | Redwood City, CA | ||
Red Tree Venture Capital | Redwood City, CA | ||
Versant Ventures | San Francisco, CA |
Jeremy Caldwell Ph.D Affiliated Funds (4)
Fund | Investor | Fund Type | Status | Vintage | Size | Dry Powder | IRR | IRR Quartile |
---|---|---|---|---|---|---|---|---|
Red Tree Venture Fund II | Red Tree Venture Capital | Venture Capital - Early Stage | Open | 2024 | ||||
Red Tree Venture Fund | Red Tree Venture Capital | Venture Capital - Early Stage | Closed | 2022 | ||||
Versant Voyageurs I | Versant Ventures | Venture - General | Closed | 2018 | ||||
Versant Venture Capital VI | Versant Ventures | Venture Capital - Early Stage | Fully Invested | 2017 |
Jeremy Caldwell Ph.D FAQs
-
Who is Jeremy Caldwell Ph.D?
Dr. Jeremy Caldwell served as Chief Executive Officer and President at Inception Sciences.
-
How much does Jeremy Caldwell Ph.D typically invest?
Jeremy Caldwell Ph.D's median deal size is
. -
What is Jeremy Caldwell Ph.D’s main position?
Jeremy Caldwell Ph.D’s primary position is Chief Executive Officer & President.
-
What are the contact details for Jeremy Caldwell Ph.D?
Jeremy Caldwell Ph.D’s email address is jc
and his phone number is +1 (925) . -
How many active board seats does Jeremy Caldwell Ph.D hold?
Jeremy Caldwell Ph.D holds 3 board seats including BioGraph 55, Odyssey Thera, and Sardona Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »